Why the study?
Studies have suggested therapies with stem cells and amniotic membrane can modulate inflammation following ischemic heart injury, but their effects on cardiac function and the NLRP3 complex needed evaluation.
Do bone-marrow mononuclear cells and acellular human amniotic membrane improve cardiac function and inhibit the NLRP3 inflammasome in a rat model of heart failure?
Do bone-marrow mononuclear cells and acellular human amniotic membrane improve cardiac function and inhibit the NLRP3 inflammasome in a rat model of heart failure?
BMMC and AHAM improve cardiac function and reduce remodeling in a rat model of heart failure, though this effect appears independent of NLRP3 inflammasome inhibition.
Recent studies have suggested that therapies with stem cells and amniotic membrane can modulate the inflammation following an ischemic injury in the heart. This study evaluated the effects of bone-marrow mononuclear cells (BMMC) and acellular human amniotic membrane (AHAM) on cardiac function and NLRP3 complex in a rat model of heart failure.On the 30th day,the echocardiographic showed improvements on ejection fraction and decreased pathological ventricular remodeling on BMMC and AHAM groups.Oxidative stress analysis was similar between the three groups,and the NLRP3 inflammasome activity were not decreased with the therapeutic use of both BMMC and AHAM,in comparison to the control group.
No takes yet. Share an insight, caveat, or question.
Takejima et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: